The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administrationChristopher D. Payne, Joseph A. Jakubowski, Ying G. Li et al.|Thrombosis and Haemostasis|2008Cited by 120
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy SubjectsNagy A. Farid, Kenneth J. Winters, David S. Small et al.|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2008Cited by 87
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometryChristopher D. Payne, Joseph A. Jakubowski, Ying G. Li et al.|Thrombosis and Haemostasis|2007Cited by 79
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjectsDavid S. Small, Christopher D. Payne, Eunice Yuen et al.|European Journal of Clinical Pharmacology|2009Cited by 75
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjectsYing G. Li, Kenneth J. Winters, Lan Ni et al.|Platelets|2009Cited by 61